Stem cell collection method before transplant in blood cancer patients
Tests G-CSF with selective plerixafor to collect stem cells in adults with myeloma or lymphoma.
Plain-language title generated from the registry record
Registry title: Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Key facts
- Where
- Philadelphia, United StatesSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are about to have an autologous stem cell transplant for multiple myeloma, Hodgkin lymphoma or non-Hodgkin lymphoma.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Multiple myeloma, Hodgkin lymphoma or non-Hodgkin lymphoma, with an autologous stem cell transplant planned.
- Earlier treatment
- People must have had stem cell mobilization with G-CSF (or biosimilars) with plerixafor, or with G-CSF (or biosimilars) alone.
Main reasons for not taking part
- Uncontrolled HIV
- Uncontrolled bacterial infection
- Active CNS disease
- Pregnancy or breastfeeding
- Another cancer, except a skin cancer treated only locally
Read by machine on 9 November 2026.
Where in United States
- Thomas Jefferson University HospitalPhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Thomas Jefferson University
- Trial code
- NCT07188090
- Record updated
- 28 November 2025
- Original description
This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome.Read full original descriptionShow less
A Prospective Trial Evaluating Plerixafor-based Mobilization and Risk of Engraftment Syndrome After Autologous Hematopoietic Stem Cell Transplantation
This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome.
The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.
Inclusion: Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:; Age ≥18 years; Undergoing autologous stem cell transplant for one of the following diagnoses:; Multiple myeloma; Hodgkin's lymphoma; Non-Hodgkin lymphoma; Karnofsky performance status of ≥ 60%; Patients must meet the TJUH BMT SOP guidelines for "Patient Criteria for Autologous HSCT" as specified below; Adequate organ function:; LVEF of ≥40%; Adjusted DLCO ≥45% of predicted corrected for hemoglobin; Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal; Serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of > 40 ml/min (excludes multiple myeloma patients receiving high dose Melphalan conditioning); Willingness to use contraception if childbearing potential; Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process; Life expectancy of > 12 months (exclusive of the disease for which the Auto HSCT is being performed); Patients must have undergone stem cell mobilization with the combination of G- CSF or biosimilars with plerixafor or G-CSF or biosimilars alone.
Exclusion: An individual who meets any of the following criteria will be excluded from participation in this study:; Uncontrolled HIV; Uncontrolled bacterial infection; Active CNS disease; Pregnancy or lactation; Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment.